CAS 475207-59-1
:Nexavar
Beschreibung:
Nexavar, mit der CAS-Nummer 475207-59-1, ist der Handelsname für Sorafenib, einen kleinen Molekül-Tyrosinkinase-Inhibitor, der hauptsächlich in der Krebsbehandlung eingesetzt wird. Er zeichnet sich durch seine Fähigkeit aus, mehrere Kinasen zu hemmen, die an der Proliferation von Tumorzellen und der Angiogenese beteiligt sind, einschließlich Raf-Kinasen und Rezeptor-Tyrosinkinasen wie VEGFR und PDGFR. Sorafenib wird typischerweise oral verabreicht und ist bekannt für seine Rolle bei der Behandlung von fortgeschrittenem Nierenzellkarzinom und hepatozellulärem Karzinom. Die Verbindung ist ein blassgelber bis schmutzig-weißer Feststoff, mit einer chemischen Formel, die Kohlenstoff, Wasserstoff, Stickstoff, Sauerstoff und Fluor enthält. Sein Wirkmechanismus besteht darin, die Signalwege zu stören, die das Wachstum von Krebszellen und die Bildung von Blutgefäßen fördern, wodurch das Tumorwachstum verlangsamt wird. Nexavar wird häufig mit Nebenwirkungen wie Müdigkeit, Durchfall und Hautreaktionen in Verbindung gebracht, die wichtige Überlegungen im Patientenmanagement sind. Insgesamt stellt Sorafenib einen bedeutenden Fortschritt in der gezielten Krebstherapie dar und bietet einen strategischen Ansatz zur Bekämpfung spezifischer Malignitäten.
Formel:C21H16ClF3N4O3·C7H8SO3
InChl:InChI=1S/C21H16ClF3N4O3.C7H8O3S/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25;1-6-2-4-7(5-3-6)11(8,9)10/h2-11H,1H3,(H,26,30)(H2,28,29,31);2-5H,1H3,(H,8,9,10)
InChI Key:InChIKey=IVDHYUQIDRJSTI-UHFFFAOYSA-N
SMILES:O(C=1C=C(C(NC)=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2.S(=O)(=O)(O)C1=CC=C(C)C=C1
Synonyme:- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1)
- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, mono(4-methylbenzenesulfonate)
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate
- BAY 43-9006 mono-p-tosylate
- Bay 54-9085
- N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea Tolsylate
- Nexavar
- Sorafenib TsOH salt
- Sorafenib p-toluenesulfonate
- Sorafenib-D3
- Sorafenib tosylate
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
19 Produkte.
Sorafenib Tosylate
CAS:Formel:C21H16ClF3N4O3·C7H8O3SReinheit:>98.0%(T)(HPLC)Farbe und Form:White to Light yellow powder to crystalMolekulargewicht:637.03Sorafenib Tosylate
CAS:Compounds containing an unfused pyridine ring in the structure, nesoiFormel:C21H16ClF3N4O3·C7H8O3SFarbe und Form:White Brown PowderMolekulargewicht:636.105724-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-methylbenzene-1-sulfonic acid
CAS:Formel:C28H24ClF3N4O6SReinheit:98%Farbe und Form:SolidMolekulargewicht:637.0266Sorafenib tosylate
CAS:<p>Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).</p>Formel:C21H16ClF3N4O3·C7H8O3SReinheit:99.24% - 99.94%Farbe und Form:White To Off-White Crystalline PowderMolekulargewicht:637.03Sorafenib tosylate
CAS:Formel:C21H16ClF3N4O3·C7H8O3SReinheit:≥ 98.0% (dried basis)Farbe und Form:White, off-white or pale yellow-brown powderMolekulargewicht:637.03Sorafenib Tosylate
CAS:Formel:C21H16ClF3N4O3·C7H8O3SFarbe und Form:Off-White SolidMolekulargewicht:464.83 172.20Sorafenib Tosylate
CAS:Kontrolliertes ProduktFormel:C21H16ClF3N4O3·C7H8O3SFarbe und Form:NeatMolekulargewicht:637.03Sorafenib tosylate
CAS:<p>Sorafenib tosylate</p>Formel:C21H16ClF3N4O3·C7H8O3SReinheit:99%Farbe und Form: off-white solidMolekulargewicht:637.03g/molSorafenib Tosylate
CAS:Kontrolliertes ProduktFormel:C21H16ClF3N4O3·C7H8O3SFarbe und Form:NeatMolekulargewicht:637.03Sorafenib tosylate
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.</p>Formel:C21H16ClF3N4O3•C7H8O3SReinheit:Min. 95%Farbe und Form:Off-White PowderMolekulargewicht:637.03 g/molSorafenib tosylate - Bio-X ™
CAS:<p>Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib tosylate also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.<br>Sorafenib tosylate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.</p>Formel:C21H16ClF3N4O3•C7H8O3SReinheit:Min. 95%Farbe und Form:PowderMolekulargewicht:637.03 g/molSorafenib, p-Toluenesulfonate Salt
CAS:Formel:C35H30F3N7O4SReinheit:98%Farbe und Form:SolidMolekulargewicht:701.73
![4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA0035M4.jpg&w=3840&q=75)
